AVE0991, a Mas receptor agonist, increases influenza and COVID-19 severity in vivo.
Melanie Wu, Julian D. J. Sng, Ellesandra C. Noye…·Kirsty Renfree Short
This study shows that AVE0991, a Mas receptor agonist, reduces cytokines and viral titres in vitro but worsens disease in vivo in viral respiratory infections.